Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

@article{Gettinger2016NivolumabMF,
  title={Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.},
  author={Scott N. Gettinger and Naiyer A Rizvi and Laura Quan Man Chow and Hossein Borghaei and Julie Renee Brahmer and Neal A. Ready and David E. Gerber and Frances A. Shepherd and Scott J. Antonia and Jonathan Wade Goldman and Rosalyn A. Juergens and Scott A. Laurie and Faith E Nathan and Yun Shen and Christopher T Harbison and Matthew D Hellmann},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 25},
  pages={
          2980-7
        }
}
PURPOSE Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial. METHODS Fifty-two patients received nivolumab 3 mg/kg intravenously every 2 weeks until progression or unacceptable toxicity; postprogression treatment was permitted per… CONTINUE READING